Scleromyxedema: Successful Treatment with Thalidomide in Two Patients
- 1 December 2006
- journal article
- case report
- Published by S. Karger AG in Dermatology
- Vol. 214 (1) , 58-60
- https://doi.org/10.1159/000096914
Abstract
Background: Scleromyxedema is an unusual skin disease characterized by mucinous infiltration of the skin. There is no satisfactory treatment for this disorder. Case Report: We report 2 cases of scleromyxedema, both associated with an IgG-λ paraprotein. Treatment with thalidomide was started and great improvement of the lesion was noted as shown by a quality of life questionnaire similar to those used in rheumatoid arthritis. TNF-α value was elevated in both cases during this treatment. Discussion: We hypothesize that the efficiency of thalidomide could be mediated by its costimulatory effect on T cytotoxic lymphocytes.Keywords
This publication has 6 references indexed in Scilit:
- Treatment of recalcitrant scleromyxedema with thalidomide in 3 patientsJournal of the American Academy of Dermatology, 2004
- Successful Treatment of Cutaneous Langerhans Cell Histiocytosis with ThalidomideDermatology, 2004
- Thalidomide as a Potential Treatment for ScleromyxedemaArchives of Dermatology, 2004
- Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysisThe Lancet, 1998
- Thalidomide Costimulates Primary Human T Lymphocytes, Preferentially Inducing Proliferation, Cytokine Production, and Cytotoxic Responses in the CD8+ SubsetThe Journal of Experimental Medicine, 1998
- Thalidomide for the Treatment of Oral Aphthous Ulcers in Patients with Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1997